---
title: "Claseprubart (DNTH103) in Generalized myasthenia gravis: Product comparison"
description: "Formulary evidence on Claseprubart (DNTH103) in Generalized myasthenia gravis: Product comparison. Topics: Claseprubart: mechanism, route, dosing interval, and approval status; Complement C5 inhibitor: Soliris; Complement C5 inhibitor: Ultomiris; Complement C5 inhibitor: Zilbrysq; 5 further topics. 9 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description/product-comparison"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-15T22:20:57-05:00"
---

# Claseprubart (DNTH103) in Generalized myasthenia gravis: Product comparison

<a id="heading-2.1.2.14"></a>

## 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

### Claseprubart: mechanism, route, dosing interval, and approval status

| Attribute | Quoted text |
| --- | --- |
| Approval status | “Claseprubart is an investigational agent that is not approved as a therapy in any indication in any jurisdiction worldwide.” |
| Mechanism of action | “potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein” |
| Route and dosing interval | “Claseprubart is designed to enable a more convenient, subcutaneous (S.C.), self-administered injection dosed as infrequently as once every two or four weeks.” |
| Regimens in the gMG phase 3 trial | “A Phase 3 registrational trial of claseprubart evaluating 300mg/2mL S.C. Q2W and 300mg/2mL S.C. Q4W in gMG patients was initiated in June” |
| Orphan drug designation | “Claseprubart was granted Orphan Drug Designation by the FDA for the treatment of Myasthenia Gravis in May 2026.” |

Source: [Dianthus Therapeutics (2026g)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000039/dnth-ex99_1.htm)

> “IV loading dose of claseprubart on Day 1 followed by SC injections of claseprubart Q2W starting at Week 1 (Day 8).”
> “Prefilled syringe containing claseprubart for SC administration”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-2.1.2.14-2"></a>

### Complement C5 inhibitor: Soliris

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “SOLIRIS® (eculizumab) injection, for intravenous use” |
| gMG indication | “the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients six years of age and older who are anti-acetylcholine receptor (AChR) antibody positive.” |
| Mechanism of action | “Eculizumab, the active ingredient in SOLIRIS, is a monoclonal antibody that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9.” |
| Adult dosing and interval in gMG | “900 mg weekly for the first 4 weeks, followed by” |
| Adult dosing and interval in gMG, continued | “1,200 mg every 2 weeks thereafter.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2007” |

Source: [Soliris prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125166s454lbl.pdf)

> “Complement inhibitors for the treatment of AChR antibody-positive gMG emerged in 2017 with eculizumab, marketed as Soliris, a recombinant humanized monoclonal antibody against complement protein C5.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-2.1.2.14-3"></a>

### Complement C5 inhibitor: Ultomiris

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “ULTOMIRIS® (ravulizumab-cwvz) injection, for intravenous use” |
| gMG indication | “the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.” |
| Mechanism of action | “Ravulizumab-cwvz is a terminal complement inhibitor that specifically binds to the complement protein C5 with high affinity” |
| Dosing interval | “maintenance doses administered every 4 or 8 weeks, starting 2 weeks after loading dose.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2018” |

Source: [Ultomiris prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761108s046lbl.pdf)

> “More recently, another C5 inhibitor, ravulizumab, marketed as Ultomiris, was approved by the FDA for the treatment of adult patients with gMG who are AChR antibody positive in 2022.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-2.1.2.14-4"></a>

### Complement C5 inhibitor: Zilbrysq

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “ZILBRYSQ® (zilucoplan) injection, for subcutaneous use” |
| gMG indication | “ZILBRYSQ is a complement inhibitor indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.” |
| Mechanism of action | “Zilucoplan binds to the complement protein C5 and inhibits its cleavage to C5a and C5b, preventing the generation of the terminal complement complex, C5b-9.” |
| Dosing interval | “The recommended dosage of ZILBRYSQ is given once daily as a subcutaneous injection and is dependent on actual body weight” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2023” |

Source: [Zilbrysq prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/216834s015lbl.pdf)

<a id="topic-2.1.2.14-5"></a>

### Neonatal Fc receptor blocker: Vyvgart

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “VYVGART® (efgartigimod alfa-fcab) injection, for intravenous use” |
| gMG indication | “VYVGART is a neonatal Fc receptor blocker indicated for the treatment of adult patients with generalized myasthenia gravis (gMG).” |
| Mechanism of action | “Efgartigimod alfa-fcab is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG.” |
| Dosing and interval | “The recommended dosage is 10 mg/kg administered as an intravenous infusion over one hour once weekly for 4 weeks.” |
| Treatment cycles | “Administer subsequent treatment cycles based on clinical evaluation.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2021” |

Source: [Vyvgart prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761195s016lbl.pdf)

<a id="topic-2.1.2.14-6"></a>

### Neonatal Fc receptor blocker: Vyvgart Hytrulo

| Attribute | Prescribing information |
| --- | --- |
| Product | “VYVGART HYTRULO is a combination of efgartigimod alfa, a neonatal Fc receptor blocker, and hyaluronidase, an endoglycosidase” |
| gMG indication | “generalized myasthenia gravis (gMG)” |
| Mechanism of action | “Efgartigimod alfa is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG.” |
| Route | “VYVGART HYTRULO is for subcutaneous use only.” |
| Self-administration | “Prefilled syringe can be administered by patients and/or caregivers.” |
| gMG dosing interval | “Administer in cycles of once weekly injections for 4 weeks.” |
| gMG dose, prefilled syringe | “Prefilled syringe: 1,000 mg efgartigimod alfa and 10,000 units hyaluronidase administered over 20 to 30 seconds.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2023” |

Source: [Vyvgart Hytrulo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761304s018lbl.pdf)

<a id="topic-2.1.2.14-7"></a>

### Neonatal Fc receptor blocker: Rystiggo

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “RYSTIGGO® (rozanolixizumab-noli) injection, for subcutaneous use” |
| gMG indication | “RYSTIGGO (rozanolixizumab-noli) is a neonatal Fc receptor blocker indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.” |
| Mechanism of action | “Rozanolixizumab-noli is a humanized IgG4 monoclonal antibody that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG.” |
| Dosing interval | “The recommended dosage is administered as a subcutaneous infusion once weekly for 6 weeks.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2023” |

Source: [Rystiggo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761286s007lbl.pdf)

<a id="topic-2.1.2.14-8"></a>

### Neonatal Fc receptor blocker: Imaavy

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “IMAAVY® (nipocalimab-aahu) injection, for intravenous use” |
| gMG indication | “generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.” |
| Mechanism of action | “Nipocalimab-aahu is a human IgG1 monoclonal antibody that binds to neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG levels.” |
| Dosing and interval | “gMG: The recommended initial dosage is 30 mg/kg once via intravenous infusion over at least 30 minutes. Two weeks after the initial dosage, administer a maintenance dosage of 15 mg/kg via intravenous infusion over at least 15 minutes, and continue every two weeks thereafter.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2025” |

Source: [Imaavy prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761430s002lbl.pdf)

<a id="topic-2.1.2.14-9"></a>

### CD19-directed B-cell depleting antibody: Uplizna

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “UPLIZNA® (inebilizumab-cdon) injection, for intravenous use” |
| gMG indication | “Generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive.” |
| Mechanism of action | “The mechanism by which inebilizumab-cdon exerts its therapeutic effects in NMOSD, IgG4-RD, and gMG is presumed to involve binding to CD19, a cell surface antigen presents on pre-B and mature B lymphocytes.” |
| Initial dosing | “Initial dose: 300 mg intravenous infusion followed two weeks later by a second 300 mg intravenous infusion.” |
| Dosing interval | “Subsequent doses (starting 6 months from the first infusion): single 300 mg intravenous infusion every 6 months.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2020” |

Source: [Uplizna prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761142s004lbl.pdf)

## Related pages
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references.md)
